Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Inclusion Criteria: * Informed consent capability * Early AD, based on episodic memory deficit and hippocampal atrophy * Age from 50 to 80, inclusive * MMSE of 20+ * Brain magnetic resonance imaging scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiver able to attend all visits with patient Exclusion Criteria: * Significant neurological disease other than AD * Major psychiatric illness * Significant systemic illness * Autoimmune disease * Prior treatment with experimental immunotherapeutics for AD including IVIG * Women of childbearing potential without birth control * Contraindication for MRI scan